Angie-Kolleen Tan
Psychiatric/Mental Health · Thousand Oaks, CANPI 1063961324
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $138,997 of the $158,882 with a category attached, or 87.5%. Teva Pharmaceuticals USA, Inc. accounts for 79.6% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $67,167, more than ten times the $2,180 reported in 2021. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 338 payments — averaging $470.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$126K
- Acadia Pharmaceuticals Inc$30K
- Otsuka America Pharmaceutical, Inc.$883
- Neurocrine Biosciences, Inc.$557
- Johnson & Johnson$388
- Alpha Cognition USA, Inc.$295
- plus $273 from 3 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$138,99787%
- Travel & lodging$11,2477%
- Food & beverage$8,1185%
- Education$2210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 256 | $126,478 |
| Acadia Pharmaceuticals Inc | 56 | $30,009 |
| Otsuka America Pharmaceutical, Inc. | 8 | $883 |
| Neurocrine Biosciences, Inc. | 6 | $557 |
| Johnson & Johnson | 4 | $388 |
| Alpha Cognition USA, Inc. | 5 | $295 |
| E.r. Squibb & Sons, L.L.C. | 1 | $123 |
| Axsome Therapeutics, Inc. | 1 | $121 |
| Medtronic | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$103,432
- NUPLAZID$29,290
- AUSTEDO$19,001
- REXULTI$741
- INGREZZA$516
- Zunveyl$416
- INVEGA TRINZA$272
- INVEGA SUSTENNA$272
- UZEDY$234
- INVEGA$149
- COBENFY$123
- ABILIFY MAINTENA$122
- ABILIFY ASIMTUFII$122
- Auvelity$121
- SPRAVATO$101
How this compares
$158,882 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 1,054 | $5,143,999 |
| NuplazidPimavanserin Tartrate | 215 | $671,823 |
| AustedoDeutetrabenazine | 86 | $545,806 |
| Invega SustennaPaliperidone Palmitate | 27 | $80,858 |
| RexultiBrexpiprazole | 50 | $60,580 |
| UzedyRisperidone | 13 | $33,709 |
| Divalproex Sodium | 317 | $11,847 |
| Clozapine | 109 | $10,867 |
| Quetiapine Fumarate | 256 | $4,598 |
| Mirtazapine | 150 | $4,092 |
| Gabapentin | 141 | $3,663 |
| Lorazepam | 445 | $2,985 |
| Duloxetine Hcl | 85 | $2,936 |
| Oxcarbazepine | 66 | $2,593 |
| Haloperidol | 76 | $2,437 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Uzedy | $126,478 | $5,723,5141,153 claims |
| Acadia Pharmaceuticals IncNuplazid | $30,009 | $671,823215 claims |
| Johnson & JohnsonInvega Sustenna | $388 | $80,85827 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $883 | $60,58050 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Thousand Oaks
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Thy LamVista$121K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
- Jonathan LlamasPasadena$31K
- John AdenijiRedlands$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.